HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.
HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.